Sarepta’s ELEVIDYS Shows Functional Benefits in Older Duchenne Patients
Event summary
- Sarepta presented new data at the 2026 World Muscle Society Congress showing ELEVIDYS provides clinically meaningful functional benefits in older ambulatory Duchenne patients (ages 8-12).
- Treatment demonstrated durable benefits across multiple measures over two years compared to external controls.
- Additional analysis showed robust micro-dystrophin expression in younger patients (ages 2-3) 12 weeks post-infusion.
- Safety profile remained consistent with previous findings, with manageable adverse events.
The big picture
Sarepta’s latest data reinforces the potential of ELEVIDYS to address a critical phase of Duchenne progression, expanding its clinical utility beyond younger patients. The findings come as gene therapies for rare diseases gain traction, with regulators increasingly focused on demonstrating long-term functional benefits. The results could bolster Sarepta’s leadership in Duchenne treatments, though sustained efficacy and regulatory approvals for broader age groups remain key hurdles.
What we're watching
- Long-term Efficacy
- Whether the observed functional benefits in older patients will be sustained over longer follow-up periods.
- Regulatory Expansion
- The pace at which Sarepta can secure approval for ELEVIDYS use in younger patients (under 4 years old).
- Competitive Positioning
- How these data will position ELEVIDYS against emerging gene therapies for Duchenne muscular dystrophy.
Related topics
